TEM vs ABT
diagnostics · comparable sales growth
| TEM diagnostics Healthcare | ABT comparable sales growth Healthcare | |
|---|---|---|
| Market | ||
| Price | $81.68 +4.08% | $110.51 +0.32% |
| Market cap | $13.2B | $188.0B |
| P/E (TTM) | — | 40.0 |
| Dividend yield | — | 1.98% |
| 52-week range | $40.77 – $91.83 | $81.97 – $132.03 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Tempus Grew Revenue 23%, But A $42.8 Million Securities Gain Helped The Loss Nov 3, 2026 | Abbott's Reported Sales Grew 14.5% But Comparable Growth Was 7%: GAAP EPS Fell To $0.53 Nov 2, 2026 |
| Latest earnings | ||
| Reported | — | Oct 21, 2026 |
| Revenue | — | — +14.5% YoY |
| EPS | — | $0.53 |
| Guidance | — | Guidance maintained |
| Revenue growth, last 4 reports | — | +14.5% |
| Topics | ||
| Main topics | ||
| Company page | Company page · Earnings releases | |
Shared topics: Margins
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.